StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.52−0.25 (-2.56%)

Close on Nov 19, 2026Market cap $1.33BP/E –Yield –

Intellia Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Intellia Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$348.69M. For fiscal 2025 it was -$395.87M. The highest annual figure on record is $29.94M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$395.87M–
FY2024Dec 31, 2024-$354.66M–
FY2023Dec 31, 2023-$408.07M–
FY2022Dec 31, 2022-$346.85M–
FY2021Dec 31, 2021-$237.79M–
FY2020Dec 31, 2020-$53.50M–
FY2019Dec 31, 2019-$110.03M–
FY2018Dec 31, 2018-$67.62M–
FY2017Dec 31, 2017-$75.37M-351.7%
FY2016Dec 31, 2016$29.94M–
FY2015Dec 31, 2015-$4.32M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$84.92M–
Q1 FY2026Mar 31, 2026-$117.43M–
Q4 FY2025Dec 31, 2025-$69.41M–
Q3 FY2025Sep 30, 2025-$76.93M–
Q2 FY2025Jun 30, 2025-$99.86M–
Q1 FY2025Mar 31, 2025-$149.67M–
Q4 FY2024Dec 31, 2024-$86.18M–
Q3 FY2024Sep 30, 2024-$86.12M–
Q2 FY2024Jun 30, 2024-$59.20M–
Q1 FY2024Mar 31, 2024-$123.17M–
Q4 FY2023Dec 31, 2023-$94.57M–
Q3 FY2023Sep 30, 2023-$105.71M–
Q2 FY2023Jun 30, 2023-$94.62M–
Q1 FY2023Mar 31, 2023-$113.16M–
Q4 FY2022Dec 31, 2022-$93.78M–
Q3 FY2022Sep 30, 2022-$82.76M–
Q2 FY2022Jun 30, 2022-$89.07M–
Q1 FY2022Mar 31, 2022-$81.23M–
Q4 FY2021Dec 31, 2021-$57.52M–
Q3 FY2021Sep 30, 2021-$69.56M–
Q2 FY2021Jun 30, 2021-$55.92M-199.2%
Q1 FY2021Mar 31, 2021-$54.79M–
Q4 FY2020Dec 31, 2020-$41.23M–
Q3 FY2020Sep 30, 2020-$29.26M–
Q2 FY2020Jun 30, 2020$56.38M–
Q1 FY2020Mar 31, 2020-$39.39M–
Q4 FY2019Dec 31, 2019-$31.23M–
Q3 FY2019Sep 30, 2019-$27.20M–
Q2 FY2019Jun 30, 2019-$28.62M–
Q1 FY2019Mar 31, 2019-$22.99M–
Q4 FY2018Dec 31, 2018-$10.13M–
Q3 FY2018Sep 30, 2018-$14.47M–
Q2 FY2018Jun 30, 2018-$23.40M–
Q1 FY2018Mar 31, 2018-$19.62M–
Q4 FY2017Dec 31, 2017-$23.70M–
Q3 FY2017Sep 30, 2017-$19.15M–
Q2 FY2017Jun 30, 2017-$16.95M–
Q1 FY2017Mar 31, 2017-$15.56M–
Q4 FY2016Dec 31, 2016-$17.82M–
Q3 FY2016Sep 30, 2016-$8.22M–

More Intellia Therapeutics figures

See a number that looks wrong?